|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRSF10 |
Gene summary for SRSF10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRSF10 | Gene ID | 10772 |
| Gene name | serine and arginine rich splicing factor 10 | |
| Gene Alias | FUSIP1 | |
| Cytomap | 1p36.11 | |
| Gene Type | protein-coding | GO ID | GO:0000244 | UniProtAcc | O75494 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10772 | SRSF10 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.74e-03 | -3.31e-01 | 0.0155 |
| 10772 | SRSF10 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.99e-09 | 7.41e-01 | 0.294 |
| 10772 | SRSF10 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.17e-05 | 5.64e-01 | 0.3859 |
| 10772 | SRSF10 | A015-C-203 | Human | Colorectum | FAP | 6.68e-19 | -1.87e-01 | -0.1294 |
| 10772 | SRSF10 | A015-C-204 | Human | Colorectum | FAP | 4.50e-02 | -8.39e-02 | -0.0228 |
| 10772 | SRSF10 | A002-C-201 | Human | Colorectum | FAP | 1.31e-05 | -1.44e-01 | 0.0324 |
| 10772 | SRSF10 | A001-C-108 | Human | Colorectum | FAP | 1.92e-13 | 1.51e-01 | -0.0272 |
| 10772 | SRSF10 | A002-C-205 | Human | Colorectum | FAP | 4.35e-13 | -1.54e-02 | -0.1236 |
| 10772 | SRSF10 | A015-C-006 | Human | Colorectum | FAP | 5.33e-13 | 1.12e-01 | -0.0994 |
| 10772 | SRSF10 | A015-C-106 | Human | Colorectum | FAP | 2.09e-09 | 8.20e-02 | -0.0511 |
| 10772 | SRSF10 | A002-C-114 | Human | Colorectum | FAP | 6.77e-09 | -1.18e-01 | -0.1561 |
| 10772 | SRSF10 | A015-C-104 | Human | Colorectum | FAP | 2.88e-22 | -6.26e-04 | -0.1899 |
| 10772 | SRSF10 | A001-C-014 | Human | Colorectum | FAP | 9.91e-08 | 2.20e-02 | 0.0135 |
| 10772 | SRSF10 | A002-C-016 | Human | Colorectum | FAP | 4.39e-12 | -1.98e-01 | 0.0521 |
| 10772 | SRSF10 | A015-C-002 | Human | Colorectum | FAP | 3.37e-05 | -1.27e-01 | -0.0763 |
| 10772 | SRSF10 | A001-C-007 | Human | Colorectum | CRC | 5.97e-03 | 3.90e-01 | 0.1899 |
| 10772 | SRSF10 | A001-C-203 | Human | Colorectum | FAP | 6.13e-06 | -2.26e-03 | -0.0481 |
| 10772 | SRSF10 | A002-C-116 | Human | Colorectum | FAP | 4.80e-24 | -3.51e-01 | -0.0452 |
| 10772 | SRSF10 | A014-C-008 | Human | Colorectum | FAP | 2.80e-06 | -1.15e-01 | -0.191 |
| 10772 | SRSF10 | A018-E-020 | Human | Colorectum | FAP | 1.09e-10 | -7.63e-02 | -0.2034 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
| GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
| GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
| GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
| GO:0022618 | Colorectum | AD | ribonucleoprotein complex assembly | 92/3918 | 220/18723 | 1.49e-12 | 2.60e-10 | 92 |
| GO:0071826 | Colorectum | AD | ribonucleoprotein complex subunit organization | 94/3918 | 227/18723 | 1.70e-12 | 2.87e-10 | 94 |
| GO:0048024 | Colorectum | AD | regulation of mRNA splicing, via spliceosome | 50/3918 | 101/18723 | 1.62e-10 | 1.56e-08 | 50 |
| GO:0050684 | Colorectum | AD | regulation of mRNA processing | 61/3918 | 137/18723 | 4.23e-10 | 3.58e-08 | 61 |
| GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
| GO:0016482 | Colorectum | AD | cytosolic transport | 68/3918 | 168/18723 | 6.00e-09 | 3.72e-07 | 68 |
| GO:1903312 | Colorectum | AD | negative regulation of mRNA metabolic process | 37/3918 | 92/18723 | 1.95e-05 | 4.01e-04 | 37 |
| GO:0000245 | Colorectum | AD | spliceosomal complex assembly | 33/3918 | 79/18723 | 2.15e-05 | 4.33e-04 | 33 |
| GO:0033119 | Colorectum | AD | negative regulation of RNA splicing | 15/3918 | 25/18723 | 2.37e-05 | 4.62e-04 | 15 |
| GO:0050686 | Colorectum | AD | negative regulation of mRNA processing | 13/3918 | 29/18723 | 3.26e-03 | 2.39e-02 | 13 |
| GO:0048025 | Colorectum | AD | negative regulation of mRNA splicing, via spliceosome | 10/3918 | 20/18723 | 3.67e-03 | 2.60e-02 | 10 |
| GO:0006376 | Colorectum | AD | mRNA splice site selection | 18/3918 | 49/18723 | 7.93e-03 | 4.73e-02 | 18 |
| GO:00083802 | Colorectum | MSS | RNA splicing | 159/3467 | 434/18723 | 1.75e-19 | 1.22e-16 | 159 |
| GO:19033112 | Colorectum | MSS | regulation of mRNA metabolic process | 115/3467 | 288/18723 | 1.23e-17 | 6.41e-15 | 115 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304042 | Liver | Cyst | Spliceosome | 19/339 | 217/8465 | 1.10e-03 | 1.22e-02 | 1.00e-02 | 19 |
| hsa0304052 | Liver | Cyst | Spliceosome | 19/339 | 217/8465 | 1.10e-03 | 1.22e-02 | 1.00e-02 | 19 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRSF10 | insertion | Nonsense_Mutation | novel | c.723_724insGCTTAAACCTTTTTAGTTATAAAACTT | p.Ser241_Gln242insAlaTerThrPheLeuValIleLysLeu | p.S241_Q242insA*TFLVIKL | O75494 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SRSF10 | SNV | Missense_Mutation | novel | c.83G>A | p.Arg28His | p.R28H | O75494 | protein_coding | tolerated(0.08) | possibly_damaging(0.495) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.184N>T | p.Arg62Cys | p.R62C | O75494 | protein_coding | tolerated(0.14) | possibly_damaging(0.767) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.602N>A | p.Ser201Tyr | p.S201Y | O75494 | protein_coding | deleterious(0) | possibly_damaging(0.675) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.665N>T | p.Arg222Ile | p.R222I | O75494 | protein_coding | deleterious_low_confidence(0.01) | benign(0.307) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.675N>T | p.Lys225Asn | p.K225N | O75494 | protein_coding | tolerated_low_confidence(0.31) | benign(0.19) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.326G>A | p.Arg109His | p.R109H | O75494 | protein_coding | tolerated(0.15) | probably_damaging(0.964) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | rs772353036 | c.481N>A | p.Asp161Asn | p.D161N | O75494 | protein_coding | tolerated(0.82) | benign(0.184) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.665N>T | p.Arg222Ile | p.R222I | O75494 | protein_coding | deleterious_low_confidence(0.01) | benign(0.307) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| SRSF10 | SNV | Missense_Mutation | novel | c.184N>T | p.Arg62Cys | p.R62C | O75494 | protein_coding | tolerated(0.14) | possibly_damaging(0.767) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10772 | SRSF10 | NA | Cynarin | CYNARIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |